Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00168259
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : January 20, 2012
Sponsor:
Collaborator:
Cellestis
Information provided by (Responsible Party):
Jennifer Hoy, The Alfred

Brief Summary:
The study is designed to evaluate interferon responses to CMV in HIV positive individuals and a component will look at interferon responses to CMV in HIV positive individuals over time after commencement of antiretroviral therapy. We will also look at the correlation between CD4 T cell numbers and HLA type with the interferon response.

Condition or disease
HIV Infection CMV Infection

Layout table for study information
Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals
Study Start Date : December 2004
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine





Biospecimen Retention:   Samples With DNA
Plasma, and DNA


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
HIV infected patients with past CMV infection initiating antiretroviral therapy
Criteria

Inclusion Criteria:

  1. HIV positive with history of documented HCV infection
  2. Over 18 years old
  3. HIV positive
  4. Antiretroviral naive, starting on antiretroviral therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168259


Locations
Layout table for location information
Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
The Alfred
Cellestis
Investigators
Layout table for investigator information
Principal Investigator: Sharon Lewin, Professor The Alfred
Layout table for additonal information
Responsible Party: Jennifer Hoy, Professor Jennifer Hoy, The Alfred
ClinicalTrials.gov Identifier: NCT00168259    
Other Study ID Numbers: 185/04
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: January 20, 2012
Last Verified: January 2012
Keywords provided by Jennifer Hoy, The Alfred:
Treatment Naive
HIV
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Communicable Diseases
Cytomegalovirus Infections
Disease Attributes
Pathologic Processes
Virus Diseases
Herpesviridae Infections
DNA Virus Infections